CVS Health Corporation (CVS)
NYSE: CVS · IEX Real-Time Price · USD
69.39
+0.79 (1.15%)
At close: Apr 18, 2024, 4:00 PM
68.78
-0.61 (-0.89%)
Pre-market: Apr 19, 2024, 8:46 AM EDT
CVS Health Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for CVS Health stock have an average target of 89.67, with a low estimate of 76 and a high estimate of 106. The average target predicts an increase of 29.23% from the current stock price of 69.39.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CVS Health stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 8 | 8 | 6 | 6 | 6 |
Buy | 12 | 12 | 12 | 13 | 13 | 12 |
Hold | 3 | 3 | 3 | 3 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 22 | 23 | 23 | 22 | 23 | 22 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $87 | Buy | Reiterates | $87 | +25.38% | Apr 10, 2024 |
Wells Fargo | Wells Fargo | Hold Maintains $83 → $76 | Hold | Maintains | $83 → $76 | +9.53% | Apr 8, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $87 | Buy | Reiterates | $87 | +25.38% | Apr 4, 2024 |
Piper Sandler | Piper Sandler | Buy Maintains $93 → $94 | Buy | Maintains | $93 → $94 | +35.47% | Mar 15, 2024 |
Barclays | Barclays | Hold Initiates $78 | Hold | Initiates | $78 | +12.41% | Mar 6, 2024 |
Financial Forecast
Revenue This Year
374.52B
from 357.78B
Increased by 4.68%
Revenue Next Year
396.71B
from 374.52B
Increased by 5.92%
EPS This Year
8.39
from 6.47
Increased by 29.64%
EPS Next Year
9.28
from 8.39
Increased by 10.67%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 396.2B | 423.3B | 461.6B | 447.7B | 471.1B |
Avg | 374.5B | 396.7B | 422.4B | 412.2B | 453.2B |
Low | 355.7B | 376.4B | 396.9B | 376.2B | 439.7B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 10.7% | 13.0% | 16.4% | 6.0% | 14.3% |
Avg | 4.7% | 5.9% | 6.5% | -2.4% | 9.9% |
Low | -0.6% | 0.5% | 0.0% | -10.9% | 6.7% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 8.82 | 10.01 | 10.98 | 12.88 | 12.18 |
Avg | 8.39 | 9.28 | 10.20 | 11.54 | 11.72 |
Low | 7.95 | 8.74 | 9.53 | 10.56 | 11.37 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 36.3% | 19.3% | 18.3% | 26.3% | 5.6% |
Avg | 29.6% | 10.7% | 9.9% | 13.1% | 1.5% |
Low | 22.8% | 4.2% | 2.6% | 3.6% | -1.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.